Evaluation of the effects of pefloxacin on platelet aggregation in vitro and ex vivo in patients suffering from chronic bronchitis.

The effects of pefloxacin on adenosine-diphosphate (ADP) and collagen-induced human platelet aggregation in vitro and ex vivo in patients suffering from chronic bronchitis were investigated. In the in vitro study carried out on platelets from 12 healthy volunteers, pefloxacin had no effect on platelet function even at a concentration of 10 mg/ml, which is 1,500 times higher than that reached in vivo. In the ex vivo study carried out in 10 patients, who received pefloxacin twice daily for 7-10 days as 400 mg oral dose, the drug did not influence platelet aggregation up to 24 hours after administration of the last oral dose.